Bioextrax AB publ OMXSTO:BIOEX:
Q3 2025 NET SALES OF SEK 227,000
Q3 2025 OPERATING RESULT OF SEK -4.4 MILLION
Q3 2025 EPS OF -0.11 SEK
Bioextrax Q3 Operating Loss At SEK 4.4 Million
Earlier from Bioextrax
- BIOEX: Improved financials and key project advances support a positive outlook for commercialization
- BIOEX: Sales growth and improved margins signal progress in Bioextrax's commercialization
- BIOEX: Cost reductions and new capital support Bioextrax’s commercial push in bioplastics
- BIOEX: Operating losses narrowed and liquidity improved, supported by new licensing deals and capital raises
- BIOEX: Licensing progress and new capital position Bioextrax for commercial breakthroughs in bioplastics
Later from Bioextrax
- Bioextrax Completes Share Issue
- Bioextrax And Chematur Sign MoU With Third Party Regarding PHBV Production
- Bioextrax Extends LOI With Major Chemical Company
- Bioextrax Files Patent Application For New PHA Purification Process
- Bioextrax: Advancements with the candy producer
Follow Bioextrax into a list and get an email when it puts out news.
Follow Bioextrax